Search AGIO
Agios Pharmaceuticals, Inc.
NasdaqGS · CIK 1439222
Last close31.8
Daily change-0.68 (-2.09%)
10 Years gain-39.82%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AGIO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
66.8Momentum
100.0Acceleration
86.0Confidence
90.0Annual Revenue15
Quarterly Revenue58
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality19.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics4.4 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.0939 percentage points.
Operating leverageOperating margin improved by 669.4495 percentage points.
ROIC expansionROIC improved by 2.9925 percentage points.
Key Metrics
Revenue Growth TTM163.31%OK
Revenue CAGR 3Y55.97%OK
Gross Margin91.53%OK
Operating Margin-511.42%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-69.2%OK
Incremental Operating Margin 3Y-98.73%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.53%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $54.03M | $47.68M | -$472.13M | -$372.98M | -$377.29M | 88.26% | -873.87% | -698.33% | -75.66% | 57.97M |
| 2025 FY Dec 31, 2024 | $36.50M | $32.33M | -$425.74M | -$389.84M | -$391.53M | 88.59% | -1,166.47% | -1,072.73% | -117.27% | 57.89M |
| 2025 FY Dec 31, 2023 | $26.82M | $23.94M | -$391.49M | -$296.06M | -$297.06M | 89.26% | -1,459.52% | -1,107.49% | -175.83% | 55.65M |
| 2024 FY Dec 31, 2022 | $14.24M | $12.54M | -$389.05M | -$309.48M | -$314.36M | 88.03% | -2,732.07% | -2,207.58% | -104.25% | 54.79M |
| 2023 FY Dec 31, 2021 | $0.00 | $0.00 | -$378.42M | -$407.32M | -$413.06M | n/a | n/a | n/a | -606.83% | 60.45M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $90.83M | sum latest 4 fiscal quarters Revenue | OK | 0001439222-26-000118, 0001439222-25-000116 |
| Revenue Growth TTM | 163.31% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001439222-26-000118, 0001439222-25-000116 |
| Revenue CAGR 3Y | 55.97% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001439222-26-000025 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001439222-26-000025 |
| Gross Profit CAGR 3Y | 56.1% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001439222-26-000025 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001439222-26-000118, 0001439222-25-000116 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 91.53% | Gross Profit / Revenue | OK | 0001439222-26-000118, 0001439222-25-000116 |
| Operating Margin | -511.42% | Operating Income / Revenue | OK | 0001439222-26-000118, 0001439222-25-000116 |
| ROIC | -69.2% | NOPAT / Average Invested Capital | OK | 0001439222-26-000118, 0001439222-25-000116 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001439222-26-000118 |
| Current Ratio | 10.22x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.53 | Revenue / Diluted Shares | OK | 0001439222-26-000118, 0001439222-25-000116 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |